氩氦刀冷冻术配合肝动脉化疗栓塞术治疗原发性肝癌  

Cryotherapy of employing Argon/Helium assisted with TACE in treating unresectable primary liver carcinoma

作　　者：张志良[1] 杨学东[1] 曹勇伟[1] 林向阳[1] 张永萍 刘亚媛 

机构地区：[1]解放军第四一一医院放射科,上海200081

出　　处：《介入放射学杂志》2004年第5期438-440,共3页Journal of Interventional Radiology

摘　　要：目的　探讨氩氦刀冷冻术配合肝动脉化疗栓塞术治疗原发性肝癌的疗效。方法　 12 4例原发性肝癌患者随机分成两组 ,对照组 6 4例 ,行肝动脉化疗栓塞治疗 ;联合治疗组 6 0例 ,行肝动脉化疗栓塞治疗加氩氦刀冷冻术。肝动脉化疗栓塞一般每月进行 1次 ,3次为一疗程 ;冷冻治疗一般每一疗程进行 1～ 3次。结果　对照组总有效率 (CR +PR) 4 5 .3% ,联合治疗组为 6 8.3% ,两组间差异有显著性。对照组半年、1年、1年半的生存率 ,分别为 81.3%、6 2 .5 %、4 3.8% ,联合治疗组分别为 93.3%、83.3%、6 3.3% ,1年和 1年半的生存率有显著差异。结论　氩氦刀冷冻术配合肝动脉化疗栓塞术治疗原发性肝癌是一种有效的方法 ,可以延长患者的生存期。Objective To investigate the effect of cryotherapy of employing Argon/Helium assisted with TACE for the unresectable primary liver carcinoma. Methods 124 cases with primary liver carcinoma were randomly divided into two groups:60 cases were treated by TACE and cryotherapy; the other 64 cases were simply done by TACE as control. In general, TACE was undertaken once a month and altogether three times for a course. Cryotherapy was undergone 1-3 times for a course. Results The total effective rates (CR+PR) were 45.3% for the control group and 68.3% for the combined therapy group, with an obvious difference between the two groups, 0.5,1,1.5 years survival rate were 81.3%,62.5%,43.8% respectively in the control group;93.3%,83.3%,63.3% respectively for the combined group. There was an obvious difference between the two groups of 1,1.5 years of survival rates. Conclusions Cryotherapy of employing Argon/Helium assisted with TACE for the unresectable primary liver carcinoma is feasible with raising the effective rate and prolonging survival time.

关 键 词：氩氦刀冷冻术 配合 肝动脉化疗栓塞术 治疗 原发性肝癌 

分 类 号：R735.7[医药卫生—肿瘤]